New combo aims to shrink liver tumors before surgery
NCT ID NCT07154082
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether giving a combination of targeted therapy (apatinib), immunotherapy (camrelizumab), and a procedure called TACE before surgery can help shrink centrally located liver tumors in people with stage B liver cancer. The goal is to make surgery more effective, reduce the risk of the cancer returning, and improve survival. The study plans to enroll 27 adults who have not had prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apatinib mesylate (a targeted therapy) and camrelizumab (an immunotherapy) combined with transarterial chemoembolization (TACE)
What this could lead to
If successful, this approach could shrink liver tumors before surgery, making them easier to remove completely and potentially lowering the chance of cancer coming back.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The combination of drugs and TACE can cause side effects like fatigue, high blood pressure, or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••